![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEib6q5Z5T1QRO-B3WCXGjv-EfMhFktGZnLAAP4ulLYgKddcRIwsR54WL0dagidB4PjfXb4aJmMfwBZleL7cuKVcq9__TVR_QRb8uDPXXqIrlpkIPP9NEFkbDuHPMLlM-9niPqhmHGDxP4bu/s320/domainnamelogo.jpg)
![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEisV8IPP5BtMOKz6R3n_OVxnpzlFUL5utLPA6n-jpXVaKorXroPB0g4CumWnU2CyKIQvYCglXLPsHJSqnlk8Mxv5zaPMaK1BYpPNTKe8XuhgPvfWEsXvO8p5A8pu9T_kx1RKq1HH5Uljrdo/s320/child4.gif)
Medicines for children
Opinions and decisions on PIP applications
EMEA decisions on paediatric investigation plans (PIPs), including deferrals and waivers, and on modification of an agreed PIP
Click on a column heading to sort alphabetically or by date.
'W' - decision granting a waiver in all age groups for all conditions / indications
'P' - decision agreeing on a Paediatric Investigation Plan, with or without partial waiver(s) and or deferral(s)
'PM' – decision on the application for modification of an agreed PIP
abrir aquí para acceder al documento basal y luego consultar las distintas moléculas:
European Medicines Agency - Human Medicines - Medicines for children - EMEA decisions on paediatric investigation plans (PIPs), including deferrals and waivers, and on modification of an agreed PIP
No hay comentarios:
Publicar un comentario